ProSomnus, Inc. Overview
Pro stress-test →ProSomnus (NASDAQ: OSA) is a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA). ProSomnus's patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes. The company addresses a massive market opportunity, as OSA affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes.
Strategic Profile
Pro stress-test →ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA. The company has built momentum since its public debut in December 2022, with record revenues and year-over-year revenue growth exceeding 50% in Q1 2023. ProSomnus devices are non-invasive, patient preferred and easy to use, with demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations.
Competitive Landscape
Pro stress-test →ProSomnus competes against CPAP manufacturers (ResMed, Philips) and alternative oral appliance providers (SomnoMed, Dental Sleep Medicine practitioners). The company's key competitive advantage is precision mass-customization using digital manufacturing, which creates personalized devices matching individual patient anatomy. Unlike traditional one-size-fits-most oral appliances, ProSomnus devices are digitally designed and milled, potentially offering superior fit and patient compliance.
Industry Context
ProSomnus, Inc. operates in Medical Devices - Sleep Medicine & Respiratory.
Key facts
Founded: 2013 · Headquarters: Pleasanton, US · Revenue: $5.8M (Q1 2023)